SOURCE: PharmaRoth Labs, Inc.

September 08, 2015 08:30 ET

PharmaRoth Labs Receives Large Purchase Order

New Retail Chain Marks Expansion for Company

LAS VEGAS, NV--(Marketwired - Sep 8, 2015) - PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, has received an additional order from its Mexican distributor Marcus De Renombre for a major retail chain in Mexico. The order is for $80,000 and represents the largest single purchase order in the company's history. The order is for Farmacias de Similares, a retailer with over 5,000 stores throughout Mexico, Guatemala, and Chile.

"This new order is from a pharmacy chain comparable to CVS Pharmacy in the US. We have been working diligently with MDR to integrate our product into this chain, and such a large first order represents why we have been so excited to do so," commented Luis Lopez, CEO of PharmaRoth.

For more information regarding Farmacias de Similares, please visit: www.farmaciasdesimilares.com.mx/ui/buscador/empresa.aspx

About Sucanon®
Sucanon® is a diabetes oral treatment containing natural ingredient. In certain countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers." Pre-clinical and clinical studies have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® is currently approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico and is distributed thought Mexico at various pharmacy chains.

For more information regarding Sucanon®, please visit www.pharmaroth.com

About PharmaRoth
PharmaRoth Labs, Inc. (OTC PINK: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.

Contact Information

  • For Investor Relations contact:

    Michael Irving
    Paramount Advisors, LLC
    (407) 878-5462
    mike@parvise.com